

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: N° 16073017				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Anti - DLL3 monoclonal antibodies, DLL3 protein, DLL3 modulators, DELTA-LIKE 3, delta-like protein 3, Delta 3, cáncer treatment, Antibody Drug Conjugates (ADCs), Pyrrolobenzodiazepine (PBDs).		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 47/48		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	CO14184798	22/Agosto/2014	Rv. 12 a 14, 18 a 36 (Pág. 153, Rv. 155 y 156 – Pág. 154, Rv. 158 – 162 - Fig. 11 A y B)	X
EPO (22/02/2017)	WO2006/065533	22/06/2006	-	A
	US2007141066	21/06/2007	-	A
	WO2013126746	29/08/2013	-	X,P
	WO2015127407	27/08/2015	-	-
	WO2014125273	21/08/2014	-	-
USPTO	US2012328624	27/12/2012	-	A
	US4676980	30/06/1987	-	
	US4816567	28/03/1989	-	
	US5112946	12/05/1992	-	
	US5122368	16/06/1992	-	
	US5223409	29/06/1993	-	
Patbase*	US2012328624	27/12/2012	-	A
	US2004259114	23/12/2004	-	
	US2011256157	20/10/2011	-	
Patent Lens	CO14184798	22/Agosto/2014	-Cadena ligera (VL) de SEQ ID NO: 204 y una cadena pesada (VH) de SEQ ID NO: 205; las cuales presentan 100% de identidad y cobertura respecto a las SEQ ID NO: 389 (VL) y SEQ ID NO: 391 (VH) reclamadas por la solicitante. - Cadena ligera (VL) de SEQ ID NO: 206 y una cadena pesada (VH) de SEQ ID NO: 207; las cuales presentan 100% de identidad y cobertura respecto a las SEQ ID NO: 393 (VL) y SEQ ID NO: 395 (VH) reclamadas por la solicitante. - Cadena ligera (VL) de SEQ ID NO: 210 y una cadena pesada (VH) de SEQ ID NO: 211; las cuales presentan 100% de identidad y cobertura respecto a las SEQ ID NO: 401 (VL) y SEQ ID NO: 403 (VH) reclamadas por la solicitante. - Cadena ligera (VL) de SEQ ID NO: 212 y una	X

			cadena pesada (VH) de SEQ ID NO: 213; las cuales presentan 100% de identidad y cobertura respecto a las SEQ ID NO: 405 (VL) y SEQ ID NO: 407 (VH) reclamadas por la solicitante.	
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente (Science Direct)	-Chapman G <i>et al.</i>, "Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis". Hum Mol Genet. Mar. 1, 2011;20(5):905-16. PMID: 21147753. -Dunwoodie <i>et al.</i>, "Mouse DLL3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo." Development. Aug. 1997;124(16):3065-76. -Geffers I <i>et al.</i>, "Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo." J Cell Biol. Jul. 30, 2007; 178(3):465-76. PMID: 17664336. -Henke RM <i>et al.</i>, "Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (DLL3) expression in the neural tube." Dev Biol. Apr. 15, 2009; 328(2):529-40 PMID:19389376. -Hoyne GF, <i>et al.</i>, "A cell autonomous role for the Notch ligand Delta-like 3 in alphabeta T-cell development." Immunol Cell Biol. Apr. 2011; 89(6):696-705. PMID: 21151194.
--	---

Fecha del reporte de búsqueda:	09/03/2018
--------------------------------	------------

Búsqueda en PatBase

TAC= (Antibod* AND DLL3) AND CPC = (C07K OR A61K)

TAC= (Antibod* AND (DLL3 OR Delta3)) AND CPC = (C07K OR A61K)

TAC= (Antibod* NEAR DLL3) AND CPC = (C07K OR A61K)

TAC= ((Antibod* AND DLL3) AND (Conjugate* NEAR Pyrrolbenzodiazepine)) CPC = (C07K OR A61K)

Title: [EN] ANTI-DLL3 ANTIBODY

Abstract: Source: US2012328624A [EN] It is intended to disclose an [antibody](#) which binds to [DLL3](#) protein. Preferably, the [antibody](#) of the present invention recognizes a region from amino acids 216 to 492 in human [DLL3](#) having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the [antibody](#) of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the [antibody](#) of the present invention and a diagnostic drug for cancer comprising the [antibody](#) of the present invention.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/395 A61K47/48 A61P35/00 C07K16/18 C07K16/28 C07K16/30 C12N15/02 C12Q1/02 C12Q1/68 G01N33/50 G01N33/574 G01N33/68 (Advanced/Invention); A61K39/00 (Advanced/Non-invention)


CPC: C07K16/3023 A61K2039/505 C07K2317/24 C07K2317/30 C07K2317/732 C07K2317/77 C07K2319/30 C12Q1/6886 C12Q2600/118 G01N33/574 G01N33/4703 A61K47/48592

European: C07K16/30D C12Q1/68M6B G01N33/574 M07K317/240 M07K317/732 M07K317/770 M07K319/30 M12Q600/118 S01N33/47A1

US: 424/139.1 424/178.1 435/375 435/7.23 530/387.9 530/391.7

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
EP2530091 A1	20121205	EP20110736812	20110128	
EP2530091 A4	20130710	EP20110736812	20110128	
JP2011093097 A1	20130530	JP20110551775T	20110128	



Title: [EN] DLL3 MODULATORS AND METHODS OF USE

Abstract: Source: US2014363455A [EN] Novel modulators, including [antibodies](#) and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Classifications: [Classification Explorer](#)


International (IPC 8-9): A61K31/407 A61K31/551 A61K31/5517 A61K39/395 A61K45/00 A61K47/42 A61K47/48 A61P11/00 A61P35/00 C07K14/47 C07K16/00 C07K16/18 C07K16/28 C07K16/30 C07K16/46 C12N1/15 C12N1/19 C12N1/21 C12N15/00 C12N15/09 C12N15/13 C12N15/63 C12N5/10 C12P21/08 G01N33/53 G01N33/563 G01N33/574 G01N33/577 (Advanced/Invention); A61K39/00 (Advanced/Non-invention); A61K A61P C07K (Subclass/Invention)

CPC: A61K31/5517 A61K2039/505 C07K16/30 A61K47/48469 A61K47/48569 C07K2317/24 C07K2317/33 C07K2317/34 C07K2317/92 C07K2319/30 A61K47/48723 C07K2317/565 A61K39/3955 A61K47/48561 A61K47/48592 C07K16/3023 C07K2317/70 C07K2317/77 G01N33/57423 G01N33/57492 G01N2333/70596 C07K2317/21 C07K2317/31 C07K2317/35 C07K2317/55 C07K2317/54 C07K2317/622 C07K16/2809 C07K2317/76 A61K47/48715 C07K16/3069 C07K2317/73 C07K16/18 A61K47/48384 A61K47/48538 C07K16/28

US: 1/1 424/130.1 424/134.1 424/139.1 424/141.1 424/178.1 424/179.1 424/181.1 435/235.1 435/252.3 435/320.1 435/325 435/326 435/352 435/354 435/358 435/69.1 435/7.23 530/387.1 530/387.3 530/387.9 530/388.1 530/391.7 530/391.9 536/23.53

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2013203459 AA	20130912	AU20130203459	20130222	
CA2865404 AA	20140822	CA20132865404	20130222	
CL2014002240 A1	20150515	CL20140002240	20140822	
CN104520324 A	20150415	CN201380010475	20130222	

Title: [EN] SITE-SPECIFIC ANTIBODY CONJUGATION METHODS AND COMPOSITIONS
[FR] PROCÉDES DE CONJUGAISON D'ANTICORPS REGIOSPECIFIQUES ET COMPOSITIONS

Abstract: Source: WO15031698A8 [EN] Provided are [antibody](#) drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders. In some aspects, the disclosure provides engineered [antibodies](#) that immunospecifically react with a determinant on tumor initiating cells, such as [DLL3](#), SEZ6, or CD324. The [antibodies](#) comprising one or more unpaired cysteine residues provide site(s) for the selective and controlled conjugation to a therapeutic or diagnostic agent.

[FR] L'invention concerne de nouveaux conjugués anticorps-médicament (ADC) et des méthodes d'utilisation de ces ADC pour traiter des troubles prolifératifs. Plus spécifiquement, l'invention porte sur un anticorps génétiquement construit qui réagit avec un déterminant de [DLL3](#), SEZ6 ou CD324. Les anticorps comprennent un ou plusieurs résidus cystéine non appariés, qui constituent un/des sites pour la conjugaison sélective et contrôlée à un agent de diagnostic ou thérapeutique.


Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K A61K31/5517 A61K38/00 A61K39/00 A61K39/395 A61K47/48 A61P35/00 C07K16/00 C07K16/18 C07K16/28 C07K16/46 C12P21/08 G01N33/574 (Advanced/Invention)

CPC: C07K16/2896 A61K2039/505 C07K2317/24 C07K2317/53 C07K2317/73 A61K47/48569 A61K47/481 A61K47/48384 G01N33/57407 A61K47/48561 G01N33/57423 C07K16/28 C07K2317/33 C07K2317/34 C07K2317/77 A61K47/48369 A61K31/5517 A61K47/48592

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2014312210 AA	20150305	AU20140312210	20140828	
AU2014312215 AA	20150305	AU20140312215	20140828	



21) Family number: 60178245 (WO15127407A1)

Similar • Translate • Full-text • Status • Citations



Title: [EN] ANTI-DLL3 ANTIBODIES AND DRUG CONJUGATES FOR USE IN MELANOMA
[FR] ANTICORPS ANTI-DLL3 ET CONJUGUES DE MEDICAMENTS DESTINES A ETRE UTILISES DANS UN MELANOME

Abstract: Source: WO15127407A1 [EN] Anti-DLL3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.

[FR] La presente invention concerne des anticorps Anti-DLL3 et des conjugues anticorps-medicament destines a etre utilises dans le diagnostic et le traitement d'un melanome.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/395 A61K47/48 G01N33/574 (Advanced/Invention)

CPC: A61K39/395 G01N33/5743 G01N2800/52 A61K47/48438 A61K47/48561 A61K47/48623

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
WO15127407 A1	20150827	WO2015US17171	20150223	

Priority: [Priority Map](#)

US20140942796P 20140221

Probable Assignee: STEMCENTRX INC

PatBase - WO15127407A1
Binding Characteristics of Anti-DLL3 Antibodies

Clone	Site	Domain	Affinity (nM)
SC18.6	E	EGF6	0.57
SC18.8	A	EGF5	0.57
SC18.10	E	EGF2	4.07
SC18.13	B	EGF2	2.09
SC18.25	G	Watermark	0.57
SC18.25	C	Watermark	0.24
SC18.34	D	EGF6	0.24
SC18.39	I	EGF6	1.07
SC18.46	A	EGF1	0.57
SC18.51	H	Watermark	2.07
SC18.54	D	EGF6	1.07
SC18.63	B	EGF2	0.49
SC18.67	D	EGF3	0.57

* Bioscience / Forthright

FIG. 5

3) Family number: 45887051 (US2011256157A)

Similar • Translate • Full-text • Status • Citations



Title: [EN] PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF

Abstract: Source: US2011256157A [EN] Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K31/5517 A61K31/5517 A61K38/05 A61K39/395 A61K47/42 A61K47/48 A61P35/00 B65D85/84 C07D C07D487/02 C07D487/04 C07D519/00 C07K16/00 C07K16/18 C07K16/28 C07K16/30 C07K17/02 C07K5/062 C07K5/065 (Advanced/Invention);

A61P35/00 (Advanced/Non-invention);

A61K47/00 A61K47/48 A61P35/00 C07D487/00 C07D487/04 (Core/Invention);

A61K31/5517 A61P35/00 C07D487/04 (Core/Non-invention);

A61K A61P C07D (Subclass/Invention)

CPC: A61K47/48638 A61K47/48561 A61K47/48584 C07D487/04 C07D519/00

European: A61K47/48T4B28 A61K47/48T4B30B A61K47/48T4B30P C07D487/04 C07D519/00

US: 206/524.1 206/524.100S 424/178.1 424/181.1 424/181.100P 530/391.7 530/391.9 530/391.900S 540/496 540/496S 540/561

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2011239507 AA	20111020	AU20110239507	20110415	
AU2011239507 BB	20150409	AU20110239507	20110415	

PatBase - US2011256157_A1
Parent Application Publication Oct. 26, 2011 Sheet 1 of 4 US 20110239507 A1




Figure 1a




Figure 1b